Rapport Therapeutics
RAPP
23.16
-0.43
-1.82%
Rapport Therapeutics
US · RAPP
#2970 by market cap
Listed 2024
23.16
-0.43
-1.82%
Periodic snapshot; not a real-time feed.
· 2026-11-20 19:30
✦ Quant Ownership Signal how this is computed
Distributing
- The number of reporting institutions decreased by 2 in the most recent period (2026/Q3).
- Total institutional ownership fell 18.2 percentage points.
Ownership vs. money flow
AlignedInstitutions trimmed shares last reporting period, and the stock has seen net outflows in main-fund flow over the last 20 trading sessions - the two line up.
Institutional ownership changes are reported quarterly with a lag; fund-flow data is daily. Treat this as a directional cross-check, not a precise timing signal.
Institutional ownership
- Held by institutions
- 89.74% -18.16pp
- Institutions
- 187 -2
- As of
- 2026/Q3 vs. prior period
Holder types
Mutual Fund43.74%
VC/PE Fund29.90%
Hedge Fund11.52%
Individual/Insider3.39%
Public Company3.36%
Insurance Company0.44%
Private Company0.36%
Endowment Fund0.21%
Government Pension Fund0.18%
Other6.90%
Top holders as of 2026-10-30
Third Rock Ventures, LLC
14.64% · 8.68M sh
FMR
12.14% · 7.20M sh
Arch Venture Partners, L.P.
6.29% · 3.73M sh
Capital Research
5.41% · 3.21M sh
BlackRock
4.86% · 2.88M sh
Cormorant Asset Management, LP
4.48% · 2.66M sh
Sofinnova Investments, Inc.
3.21% · 1.90M sh
Johnson & Johnson Innovation - JJDC, Inc.
3.01% · 1.78M sh
The Goldman Sachs Group, Inc.
2.81% · 1.66M sh
Polar Capital Holdings Plc
2.71% · 1.61M sh
Bar length is relative to the largest holder shown here, not to 100% of the company.
Insiders
50 filings tracked · 22 buys · 28 sells
| Name | Role | Stake |
|---|---|---|
| Third Rock Ventures, LLC | -- | 14.64% |
| Steven Paul | Founder & Independent Chairman | 0.94% |
| Abraham Ceesay | CEO, President, Treasurer & Director | 0.93% |
| David Bredt | Founder & Chief Scientific Officer | 0.66% |
| Swamy Yeleswaram | Chief Development Officer | 0.33% |
| Cheryl Gault | Chief Operating Officer | 0.22% |
| Bradley Galer | Former Chief Medical Officer | 0.19% |
| Reid Huber | Director | 0.03% |
| Troy Ignelzi | Chief Financial Officer | 0.03% |
| Wendy Young | Independent Director | 0.02% |
Insider transactions most recent Form 4 filings
| Date | Name | Role | Type | Shares | Price |
|---|---|---|---|---|---|
| 2026-10-29 | Third Rock Ventures, LLC | -- | Private Acquisition | +1,428,571 | $21.00 |
| 2026-10-22 | Raymond Sanchez | Independent Director | Open Market Acquisition | +3,600 | $27.35 |
| 2026-10-21 | John Michael Maraganore | Independent Director | Open Market Acquisition | +9,411 | $26.38–26.92 |
| 2026-10-21 | Steven Paul | Founder & Independent Chairman | Open Market Acquisition | +35,714 | $27.28 |
| 2026-10-21 | Paul Silva | Independent Director | Open Market Acquisition | +3,680 | $27.08 |
| 2026-10-21 | Wendy Young | Independent Director | Open Market Acquisition | +3,789 | $26.39 |
| 2026-10-20 | Troy Ignelzi | Chief Financial Officer | Open Market Acquisition | +5,500 | $26.10 |
| 2026-10-20 | Abraham Ceesay | CEO, President, Treasurer & Director | Automatic Disposition | -2,210 | $29.16 |
| 2026-10-06 | Abraham Ceesay | CEO, President, Treasurer & Director | Automatic Disposition | -4,522 | $30.66–32.03 |
| 2026-10-05 | Abraham Ceesay | CEO, President, Treasurer & Director | Intent to Sell (Form 144) | -39,470 | $31.15 |
| 2026-09-29 | Cheryl Gault | Chief Operating Officer | Automatic Disposition | -10,000 | $33.04–33.76 |
| 2026-09-22 | Abraham Ceesay | CEO, President, Treasurer & Director | Automatic Disposition | -2,210 | $39.05–41.05 |
| 2026-09-07 | Abraham Ceesay | CEO, President, Treasurer & Director | Automatic Disposition | -8,210 | $45.56–46.01 |
| 2026-08-24 | Abraham Ceesay | CEO, President, Treasurer & Director | Automatic Disposition | -18,921 | $49.57 |
| 2026-08-24 | Swamy Yeleswaram | Chief Development Officer | Automatic Disposition | -50,160 | $50.00–51.06 |
| 2026-08-18 | Swamy Yeleswaram | Chief Development Officer | Automatic Disposition | -404 | $49.90 |
| 2026-08-10 | Abraham Ceesay | CEO, President, Treasurer & Director | Automatic Disposition | -51,499 | $45.97–48.62 |
| 2026-07-26 | Abraham Ceesay | CEO, President, Treasurer & Director | Automatic Disposition | -2,210 | $42.11–42.74 |
| 2026-07-13 | Abraham Ceesay | CEO, President, Treasurer & Director | Automatic Disposition | -8,210 | $39.72–40.57 |
| 2026-06-29 | Cheryl Gault | Chief Operating Officer | Automatic Disposition | -10,000 | $40.09–43.15 |
Form 4 filings, most recent per company. "Other Derivative Acquisition" rows are mostly RSU/option vesting, not open-market buying - the Type column says which.
Quote time 2026-11-20 19:30:06 · For reference only, not investment advice and not tailored to your situation.
Rapport Therapeutics discussion 0 comments